Disease: Fatty Liver ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.150 Biomarker disease BEFREE Given that PCSK9 degrades the LDL receptor (LDLR) and prevents the removal of LDL from the blood into the liver, in the present study we examined the effect of hepatic steatosis on LDLR expression and circulating LDL cholesterol levels. 31004037 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.150 AlteredExpression disease BEFREE Circulating PCSK9 levels are closely related to hepatic steatosis severity and endogenous estrogen levels. 31085239 2019
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.150 AlteredExpression disease BEFREE Thus, it is evident that sauchinone reduces hepatic steatosis by downregulating the expression of hepatic PCSK9 via SREBP-2. 29712938 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.150 Biomarker disease BEFREE Circulating PCSK9 concentrations are not associated with the severity of liver steatosis or histological markers of NASH. 30261472 2018
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.150 GeneticVariation disease BEFREE Methods Subjects from the PLIC cohort were genotyped for the loss-of-function PCSK9 R46L variant and characterized for clinical and biochemical parameters, total and android fat mass, hepatic steatosis and epicardial fat thickness. 28758421 2017
CUI: C0015695
Disease: Fatty Liver
Fatty Liver 		0.150 Biomarker disease HPO